CommercialCoverageMedium impact
07.07.09j, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, Sports Medicine +1 more·Medical Policy
Effective date
Jan 6, 2025
We identified it
Jun 19, 2026
Summary
IBX updated their medical policy for stem-cell therapy, platelet-rich plasma (PRP) for orthopedic applications, and PRP/platelet-derived growth factor for wound healing and other non-orthopedic conditions. This involves changes to coverage and reimbursement positions as well as general guidelines.
Action Required
By January 6, 2025: Billing team must review the updated IBX policy 07.07.09j for stem-cell therapy and PRP treatments to understand new coverage and reimbursement changes. Access the full policy at the IBX medical policy website to identify specific billing requirements and coverage criteria. Inform providers of any documentation requirements for stem-cell and PRP procedures.